Skip to content
2000
  1. Home
  2. A-Z Publications
  3. The International Journal of Gastroenterology and Hepatology Diseases
  4. Volume 1, Issue 1
  5. Article
Volume 1, Issue 1
  • ISSN: 2666-2906
  • E-ISSN: 2666-2914

Abstract

Drug-induced liver injury (DILI) and the causative drug in patients under polypharmacy medication represent a challenging diagnosis.

A 73 years old multimorbid man receiving polypharmacy, including rosuvastatin among other drugs, presented with high values of alanine aminotransferase (950 U/L) and aspartate aminotransferase (702 U/L), associated with a normal value of alkaline phosphatase (46 U/L), which turned out as DILI due to the hepatocellular injury type with an R-value of 29.8 as calculated from liver test values. Causality for each drug was assessed using the updated RUCAM (Roussel Uclaf Causality Assessment Method) prospectively. Causality for rosuvastatin and diltiazem was highly probable based on a RUCAM score of 9, but no reports of DILI caused by diltiazem were found. In addition, the causality grade for other drugs included in the patient’s medication was “probable” based on a RUCAM score of 6 to 8. The patient experienced a favorable outcome after discontinuation of all medication.

The medication history, as well as the prospective and proactive causality evaluation by the updated RUCAM, helped establish the diagnosis of severe DILI by two highly suspected causative drugs, considering also several drugs with a “probable” causality grade in this case. Statins may cause direct damage to the liver, interact with other drugs, and enhance the susceptibility to DILI caused by commonly safe drugs.

In this case, the DILI was caused by rosuvastatin as evidenced by a high score in the updated RUCAM, but a large number of comedications may have a co-triggering effect.

© 2022 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ijghd/10.2174/2666290601666220425104715
2022-04-01
2024-11-26

  • From This Site

    /content/journals/ijghd/10.2174/2666290601666220425104715
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MarroneG. VaccaroF.G. BiolatoM. MieleL. LiguoriA. AraneoC. PonzianiF.R. MoresN. GasbarriniA. GriecoA. Drug-induced liver injury 2017: The diagnosis is not easy but always to keep in mind.Eur. Rev. Med. Pharmacol. Sci.2017211Suppl.12213428379587
     [Google Scholar]
  2. HoofnagleJ.H. BjörnssonE.S. Drug-induced liver injury - Types and phenotypes.N. Engl. J. Med.2019381326427310.1056/NEJMra181614931314970
     [Google Scholar]
  3. DananG. TeschkeR. RUCAM in drug and herb induced liver injury: The update.Int. J. Mol. Sci.20151711410.3390/ijms1701001426712744
     [Google Scholar]
  4. DananG. BénichouC. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries.J. Clin. Epidemiol.199346111323133010.1016/0895‑4356(93)90101‑68229110
     [Google Scholar]
  5. BénichouC. DananG. FlahaultA. Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge.J. Clin. Epidemiol.199346111331133610.1016/0895‑4356(93)90102‑78229111
     [Google Scholar]
  6. BénichouC. Criteria of drug-induced liver disorders. Report of an international consensus meeting.J. Hepatol.199011227227610.1016/0168‑8278(90)90124‑A2254635
     [Google Scholar]
  7. NCBI. LiverTox: Clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Rosuvastatin, 2012. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548620/
  8. ChalasaniN. BonkovskyH.L. FontanaR. LeeW. StolzA. TalwalkarJ. ReddyK.R. WatkinsP.B. NavarroV. BarnhartH. GuJ. SerranoJ. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study.Gastroenterology20151487134052.e710.1053/j.gastro.2015.03.00625754159
     [Google Scholar]
  9. NCBI. LiverTox: Clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Diltiazem, 2012. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547898/
  10. BjörnssonE.S. HoofnagleJ.H. Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports.Hepatology201663259060310.1002/hep.2832326517184
     [Google Scholar]
  11. BjörnssonE.S. Hepatotoxicity by drugs: The most common implicated agents.Int. J. Mol. Sci.201617222410.3390/ijms1702022426861310
     [Google Scholar]
  12. TeschkeR. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf causality assessment method.Expert Opin. Drug Metab. Toxicol.201814111169118710.1080/17425255.2018.153907730354694
     [Google Scholar]
  13. RosenbergJ. HigleyC. LewisJ.H. Selected highlights from the recent literature of newly reported herbal and dietary supplement-induced liver injury.Adv. Res. Gastroenterol. Hepatol.202015155590410.19080/ARGH.2020.15.555904
     [Google Scholar]
  14. TraverseJ.H. SwensonL.J. McBrideJ.W. Acute hepatic injury after treatment with diltiazem.Am. Heart J.199412761636163910.1016/0002‑8703(94)90402‑28197999
     [Google Scholar]
  15. TeschkeR. DananG. Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993-mid 2020: A comprehensive analysis.Medicines (Basel)202071013910.3390/medicines710006233003400
     [Google Scholar]
  16. ShahJ. LingiahV. PyrsopoulosN. GalanM. Acute liver injury in a patient treated with rosuvastatin: A rare adverse effect.Gastroenterol. Res.201912526326610.14740/gr121231636777
     [Google Scholar]
  17. ShepherdJ. HunninghakeD.B. SteinE.A. KasteleinJ.J.P. HarrisS. PearsJ. HutchinsonH.G. Safety of rosuvastatin.Am. J. Cardiol.200494788288810.1016/j.amjcard.2004.06.04915464670
     [Google Scholar]
  18. HwangN.K. ParkJ.S. ChaK.S. KangJ.S. Hepatotoxicity associated with a short course of rosuvastatin.Chin. Med. J. (Engl.)2015128121693169410.4103/0366‑6999.15838226063377
     [Google Scholar]
  19. NaiqiongW. LianshengW. ZhanyingH. YuanlinG. ChenggangZ. YingG. QianD. DongchenL. YanjunZ. JianjunL. A multicenter and randomized controlled trial of bicyclol in the treatment of statin-induced liver injury.Med. Sci. Monit.2017235760576610.12659/MSM.90409029200411
     [Google Scholar]
  20. FamularoG. MieleL. MinisolaG. GriecoA. Liver toxicity of rosuvastatin therapy.World J. Gastroenterol.20071381286128810.3748/wjg.v13.i8.128617451217
     [Google Scholar]
  21. TeschkeR. Idiosyncratic DILI: Analysis of 46,266 cases assessed for causality by RUCAM and published from 2014 to early 2019.Front. Pharmacol.20191073010.3389/fphar.2019.0073031396080
     [Google Scholar]
  22. TeschkeR. ZhuY. Paracetamol (acetaminophen), alcohol, and liver injury: Biomarkers, clinical issues, and experimental aspects.SL Pharmacol. Toxicol.20181113
     [Google Scholar]
  23. TeschkeR. Acetaminophen syn. paracetamol: Acute liver injury and acute on chronic liver failure with case analysis and causality assessment using RUCAM.In: Liver Failure: Acute and Acute on Chronic. PyrsopoulosN.T. Cham, SwitzerlandSpringer Nature202010.1007/978‑3‑030‑50983‑5_12
     [Google Scholar]
  24. UetrechtJ. Mechanistic studies of idiosyncratic DILI: Clinical implications.Front. Pharmacol.20191083710.3389/fphar.2019.0083731402866
     [Google Scholar]
  25. TeschkeR. UetrechtJ. Mechanism of idiosyncratic drug induced liver injury (DILI): Unresolved basic issues.Ann. Transl. Med.20219873010.21037/atm‑2020‑ubih‑0533987428
     [Google Scholar]
  26. LammertC. EinarssonS. SahaC. NiklassonA. BjornssonE. ChalasaniN. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals.Hepatology20084762003200910.1002/hep.2227218454504
     [Google Scholar]
  27. LammertC. BjornssonE. NiklassonA. ChalasaniN. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events.Hepatology201051261562010.1002/hep.2331719839004
     [Google Scholar]
  28. ThakkarS. ChenM. HongH. LiuZ. FangH. TongW. Drug-induced liver injury (DILI) classification and its application on human DILI risk prediction.In: Drug-Induced Liver Toxicity. ChenM. WillY. Springer Nature2018455910.1007/978‑1‑4939‑7677‑5_3
     [Google Scholar]
  29. ChenM. BorlakJ. TongW. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury.Hepatology201358138839610.1002/hep.2620823258593
     [Google Scholar]
  30. ChenM. SuzukiA. BorlakJ. AndradeR.J. LucenaM.I. Drug-induced liver injury: Interactions between drug properties and host factors.J. Hepatol.201563250351410.1016/j.jhep.2015.04.01625912521
     [Google Scholar]
  31. WengZ. WangK. LiH. ShiQ. A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications.Oncotarget2015619170311703810.18632/oncotarget.440026220713
     [Google Scholar]
  32. BjörnssonE. JacobsenE.I. KalaitzakisE. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing.J. Hepatol.201256237438010.1016/j.jhep.2011.07.02321889469
     [Google Scholar]
  33. BaderT. The myth of statin-induced hepatotoxicity.Am. J. Gastroenterol.2010105597898010.1038/ajg.2010.10220445507
     [Google Scholar]
  34. BaderT. Yes! Statins can be given to liver patients.J. Hepatol.201256230530710.1016/j.jhep.2011.08.01621963520
     [Google Scholar]
  35. SchulzeJ. GlassX. Statin hepatotoxicity and the dilemma of causality in rare hepatic adverse drug reactions.J. Hepatol.201257370270310.1016/j.jhep.2012.03.01022510260
     [Google Scholar]
  36. BaderT. Reply to: “Statin hepatotoxicity and the dilemma of causality in rare hepatic adverse drug reactions.J. Hepatol.201257370370410.1016/j.jhep.2012.04.001
     [Google Scholar]
  37. TeschkeR. Hepatotoxicity associated with statins.Ann. Hepatol.201211341842010.1016/S1665‑2681(19)30943‑322481466
     [Google Scholar]
  38. KeL. LuC. ShenR. LuT. MaB. HuaY. Knowledge mapping of drug-induced liver injury: A scientometric investigation (2010-2019).Front. Pharmacol.20201184210.3389/fphar.2020.0084232581801
     [Google Scholar]
  39. SargesP. SteinbergJ.M. LewisJ.H. Drug-Induced liver injury: Highlights from a review of the 2015 literature.Drug Saf.201639980182110.1007/s40264‑016‑0427‑827142208
     [Google Scholar]
  40. ShahbazO. MahajanS. LewisJ.H. Highlights of drug - and herb- induced liver injury in the literature from 2016: How best to translate new information into clinical practice?Expert Opin. Drug Metab. Toxicol.201713993595110.1080/17425255.2017.136239128772086
     [Google Scholar]
  41. TeschkeR. SchulzeJ. EickhoffA. DananG. Drug induced liver injury: Can biomarkers assist RUCAM in causality assessment?Int. J. Mol. Sci.201718480310.3390/ijms1804080328398242
     [Google Scholar]
  42. TeschkeR. EickhoffA. BrownA.C. NeumanM.G. SchulzeJ. Diagnostic biomarkers in liver injury by drugs, herbs, and alcohol: Tricky dilemma after EMA correctly and officially retracted letter of support.Int. J. Mol. Sci.201921121210.3390/ijms2101021231892250
     [Google Scholar]
  43. TeschkeR. AndradeR.J. Drug-induced liver injury: Expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment.Gastroenterology201514871271127310.1053/j.gastro.2015.04.02725921378
     [Google Scholar]
  44. TeschkeR. AndradeR.J. Drug, herb, and dietary supplement hepatotoxicity.Int. J. Mol. Sci.2016179148810.3390/ijms1709148827608014
     [Google Scholar]
  45. TeschkeR. DananG. Drug induced liver injury with analysis of alternative causes as confounding variables.Br. J. Clin. Pharmacol.20188471467147710.1111/bcp.1359329607530
     [Google Scholar]
/content/journals/ijghd/10.2174/2666290601666220425104715
Loading
Severe DILI in a Patient under Polypharmacy Including Rosuvastatin: Diagnostic Challenges and Lessons from a Case Report Assessed Using the Updated RUCAM Algorithm
Int J Gastroenterol Hepatol Dis 1, e250422203997 (2022); https://doi.org/10.2174/2666290601666220425104715
/content/journals/ijghd/10.2174/2666290601666220425104715
/content/journals/ijghd/10.2174/2666290601666220425104715
Loading

Data & Media loading...


  • Article Type:     Case Report
Keyword(s): case report; Drug induced liver injury (DILI); liver injury; polypharmacy; roussel uclaf causality assessment method (RUCAM); statins

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test